-
11.发明申请HLA CLASS I A2 TUMOR ASSOCIATED ANTIGEN PEPTIDES AND VACCINE COMPOSITIONS 审中-公开HLA I类A2肿瘤相关抗原肽和疫苗组合物公开(公告)号：US20110318408A1
公开(公告)日：2011-12-29
申请号：US13155307
申请日：2011-06-07
申请人： John D. Fikes , Alessandro Sette , John Sidney , Scott Southwood , Esteban Celis , Elissa A. Keogh , Robert Chesnut
发明人： John D. Fikes , Alessandro Sette , John Sidney , Scott Southwood , Esteban Celis , Elissa A. Keogh , Robert Chesnut
IPC分类号： A61K9/127 , C07K7/08 , C07K14/00 , A61K39/00 , C12N5/0784
CPC分类号： A61K9/0019 , A61K9/127 , A61K38/08
摘要： A composition or vaccine composition comprising at least one peptide that has less than 600 contiguous amino acids having 100% identity to a native sequence of CEA, HER2/neu, MAGE2, MAGE3, or p53, the peptide further comprising at least one epitope selected from Table 6.
摘要翻译： 一种组合物或疫苗组合物，其包含至少一种具有小于600个连续氨基酸的肽，其具有与CEA，HER2 / neu，MAGE2，MAGE3或p53的天然序列具有100％同一性，所述肽还包含至少一个选自 表6。
-
12.发明授权Expression vectors for stimulating an immune response and methods of using the same 有权用于刺激免疫应答的表达载体及其使用方法公开(公告)号：US06534482B1
公开(公告)日：2003-03-18
申请号：US09311784
申请日：1999-05-13
申请人： John D. Fikes , Gary G. Hermanson , Alessandro Sette , Glenn Y. Ishioka , Brian Livingston , Robert W. Chesnut
发明人： John D. Fikes , Gary G. Hermanson , Alessandro Sette , Glenn Y. Ishioka , Brian Livingston , Robert W. Chesnut
IPC分类号： A61K4800
CPC分类号： C07K14/70539 , A01K2217/05 , A61K38/00 , A61K39/385 , A61K2039/605 , C07K14/005 , C07K14/445 , C07K2319/00 , C07K2319/02 , C12N2730/10122 , C12N2740/16122 , C12N2740/16222 , C12N2740/16322 , C12N2770/24222 , Y02A50/412
摘要： The present invention relates to nucleic acid vaccines encoding multiple CTL and HTL epitopes and MHC targeting sequences.
摘要翻译： 本发明涉及编码多种CTL和HTL表位和MHC靶向序列的核酸疫苗。
-
13.发明授权公开(公告)号：US06602510B1
公开(公告)日：2003-08-05
申请号：US09543608
申请日：2000-04-05
申请人： John D. Fikes , Alessandro Sette , John Sidney , Scott Southwood , Esteban Celis , Elissa A. Keogh , Robert Chesnut
发明人： John D. Fikes , Alessandro Sette , John Sidney , Scott Southwood , Esteban Celis , Elissa A. Keogh , Robert Chesnut
IPC分类号： A61K3808
CPC分类号： A61K39/0011 , A61K38/00 , A61K39/00 , A61K45/06 , A61K2039/5154 , C07K14/4748 , C07K14/705 , C07K14/70539
摘要： A composition or vaccine composition comprising eight isolated epitopes consisting of YLSGANLNV (SEQ. ID. NO: 1), IMIGVLVGV (SEQ. ID. NO: 2), KLBPVQLWV (SEQ. ID. NO: 3), SMPPPGTRV (SEQ. ID. NO: 4), KVAELVHFL (SEQ. ID. NO: 5), YLQLVFGIEV (SEQ. ID. NO: 6), RLLQETELV (SEQ. ID. NO: 7), and, VVLGVVFGI (SEQ. ID. NO: 8).
摘要翻译： 包含由YLSGANLNV（SEQ ID NO：1），IMIGVLVGV（SEQ ID NO：2），KLBPVQLWV（SEQ.ID.NO:3），SMPPPGTRV（SEQ ID NO：1），SEQ ID NO：3组成的8个分离的表位的组合物或疫苗组合物。 （SEQ ID NO：5），YLQLVFGIEV（SEQ ID NO：6），RLLQETELV（SEQ ID NO：7）和VVLGVVFGI（SEQ ID NO：8） 。
-
公开(公告)号：US09394350B2
公开(公告)日：2016-07-19
申请号：US14081086
申请日：2013-11-15
CPC分类号： A61K39/0011 , A61K39/39 , A61K2039/55511 , A61K2039/55566 , A61K2039/57 , A61K2039/572 , A61K2039/70 , C07K7/06 , C07K14/47
摘要： A peptide or composition comprising at least one HLA-A2 epitope or analog from CEA, HER2/neu, MAGE2, MAGE3, or p53.
摘要翻译： 包含至少一种HLA-A2表位或CEA，HER2 / neu，MAGE2，MAGE3或p53的类似物的肽或组合物。
-
15.发明授权Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions 有权使用肽和核酸组合物诱导恶性疟原虫的细胞免疫应答公开(公告)号：US09266930B1
公开(公告)日：2016-02-23
申请号：US09390061
申请日：1999-09-03
申请人： Alessandro Sette , John Sidney , Scott Southwood , Brian D. Livingston , Robert Chestnut , Denise Marie Baker , Esteban Celis , Ralph T. Kubo , Howard M. Grey
发明人： Alessandro Sette , John Sidney , Scott Southwood , Brian D. Livingston , Robert Chestnut , Denise Marie Baker , Esteban Celis , Ralph T. Kubo , Howard M. Grey
IPC分类号： A61K39/002 , A61K39/015 , C07K14/44 , C07K14/445 , A61K39/00
CPC分类号： A61K39/015 , A61K39/0011 , A61K39/002 , A61K2039/5154 , A61K2039/55566 , A61K2039/57 , A61K2039/572 , A61K2039/605 , C07K7/08 , C07K14/005 , C07K14/445 , C07K14/70539 , C07K2319/00 , C07K2319/01 , C12N2730/10122 , C12N2740/16122 , C12N2740/16222 , C12N2740/16322 , C12N2770/24222 , Y02A50/412
摘要： This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare Plasmodium falciparum epitopes, and to develop epitope-based vaccines directed towards malaria. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of malaria. In particular, this application discloses isolated peptides comprising oligopeptides, for example the oligopeptide GVSENIFLK, or isolated peptides conjugated with T helper peptides that are used as antigens in epitope-based vaccines to prevent and/or treat malaria.
摘要翻译： 本发明使用我们对抗原被T细胞识别和制备恶性疟原虫表位的机制的知识，并开发针对疟疾的基于表位的疫苗。 更具体地说，本申请将我们发现的药物组合物和使用方法用于预防和治疗疟疾。 特别地，本申请公开了分离的肽，其包含寡肽，例如寡肽GVSENIFLK，或与T辅助肽缀合的分离肽，其用作基于表位的疫苗中的抗原以预防和/或治疗疟疾。
-
16.发明申请公开(公告)号：US20120141465A1
公开(公告)日：2012-06-07
申请号：US11867621
申请日：2007-10-04
CPC分类号： C07K16/2878 , A61K39/12 , A61K2039/505 , A61K2039/5254 , A61K2039/55516 , C07K2317/75 , C12N2710/24134
摘要： The invention relates to compositions and methods that employ OX40 (CD134), a TNFR superfamily protein, agonists. The invention includes among other things administering an OX40 agonist alone or in combination with a viral antigen, or live or attenuated virus, to treat a viral infection, or for vaccination or immunization.
摘要翻译： 本发明涉及使用OX40（CD134），TNFR超家族蛋白质激动剂的组合物和方法。 本发明包括单独施用OX40激动剂或与病毒抗原或活或减毒病毒组合以治疗病毒感染或用于疫苗接种或免疫接种的本发明。
-
17.发明授权Inducing cellular immune responses to hepatitis B virus using peptide compositions 有权使用肽组合物诱导对乙型肝炎病毒的细胞免疫应答公开(公告)号：US07611713B2
公开(公告)日：2009-11-03
申请号：US10654601
申请日：2003-09-04
申请人： Alessandro Sette , John Sidney , Scott Southwood , Maria Vitiello , Brian Livingston , Esteban Celis , Ralph Kubo , Howard Grey , Robert Chesnut
发明人： Alessandro Sette , John Sidney , Scott Southwood , Maria Vitiello , Brian Livingston , Esteban Celis , Ralph Kubo , Howard Grey , Robert Chesnut
CPC分类号： C07K14/005 , A61K38/00 , C07K14/70539 , C12N2730/10122
摘要： This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to develop epitope-based vaccines directed towards HBV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HBV infection.
摘要翻译： 本发明使用我们对T细胞识别抗原的机制的知识来开发针对HBV的基于表位的疫苗。 更具体地说，本申请介绍了我们在预防和治疗HBV感染中的药物组合物和使用方法的发现。
-
公开(公告)号：US20070054262A1
公开(公告)日：2007-03-08
申请号：US10551209
申请日：2004-03-29
IPC分类号： C12Q1/70 , G01N33/569 , G01N33/554 , G01N33/53
CPC分类号： C07K7/06 , C07K7/08 , C12N2740/16211 , C12N2740/16311 , C12N2770/24211 , G01N33/569 , G01N33/6878 , G01N2333/70539 , Y02A50/53 , Y02A50/55 , Y02A50/58 , Y02A90/26
摘要： The present invention is directed to methods for selecting a variant of a peptide epitope which induces a CTL response against another variant(s) of the peptide epitope, by determining whether the variant comprises only conserved residues, as defined herein, at non-anchor positions in comparison to the other variant(s). The present invention is also directed to variants identified by the methods above; peptides comprising such variants; nucleic acids encoding such variants and peptides; cells comprising such variants, and/or peptides, and/or nucleic acids; compositions comprising such variants, and/or peptides, and/or nucleic acids, and/or cells; as well as therapeutic and diagnostic methods for using such variants, peptides, nucleic acids, cells, and compositions.
摘要翻译： 本发明涉及通过确定该变体是否仅包含如本文定义的保守残基在非锚定位置上选择诱导针对肽表位的另一个变体的CTL应答的肽表位变体的方法 与其他变体相比。 本发明还涉及通过上述方法鉴定的变体; 包含这些变体的肽; 编码这种变体和肽的核酸; 包含这些变体的细胞和/或肽和/或核酸; 包含这些变体的组合物和/或肽，和/或核酸和/或细胞; 以及使用这些变体，肽，核酸，细胞和组合物的治疗和诊断方法。
-
19.发明申请Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions 有权使用肽和核酸组合物诱导对乙型肝炎病毒的细胞免疫应答公开(公告)号：US20050063983A1
公开(公告)日：2005-03-24
申请号：US10654601
申请日：2003-09-04
申请人： Alessandro Sette , John Sidney , Scott Southwood , Maria Vitiello , Brian Livingston , Esteban Celis , Ralph Kubo , Howard Grey , Robert Chesnut
发明人： Alessandro Sette , John Sidney , Scott Southwood , Maria Vitiello , Brian Livingston , Esteban Celis , Ralph Kubo , Howard Grey , Robert Chesnut
CPC分类号： C07K14/005 , A61K38/00 , C07K14/70539 , C12N2730/10122
摘要： This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to develop epitope-based vaccines directed towards HBV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HBV infection.
摘要翻译： 本发明使用我们对T细胞识别抗原的机制的知识来开发针对HBV的基于表位的疫苗。 更具体地说，本申请介绍了我们在预防和治疗HBV感染中的药物组合物和使用方法的发现。
-
公开(公告)号：US6156316A
公开(公告)日：2000-12-05
申请号：US437175
申请日：1995-05-08
IPC分类号： A61K39/00 , A61P35/00 , C07K14/47 , C07K14/705 , C07K14/74 , C07K14/82 , C12N15/62 , G01N33/569 , G01N33/574 , G01N33/68 , C07K7/00
CPC分类号： C07K14/47 , C07K14/70539 , C07K14/70567 , C07K14/82 , C12N15/62 , G01N33/56977 , G01N33/57426 , G01N33/6878 , A61K39/00 , C07K2319/40 , C07K2319/81
摘要： Fusion-point spanning peptides, for example BCR-ABL fusion breakpoint peptides associated with chronic myelogenous leukemia (CML), bind major histompatibility complex molecules, such as HLA class I molecules, and induce cytotoxic T cell proliferation. The breakpoint peptides can be used as vaccines.
摘要翻译： 融合点跨越肽，例如与慢性骨髓性白血病（CML）相关的BCR-ABL融合断点肽，结合主要的histompatibility复合分子，如HLA I类分子，并诱导细胞毒性T细胞增殖。 断点肽可用作疫苗。
-
-
-
-
-
-
-
-
-
搜索结果
60 条记录 (耗时 0.052 秒)
